Liaoning Chengda Biotechnology (688739.SH): Influenza Virus Split Vaccine (High Dose) Enters Phase I Clinical Trial.

Liaoning Chengda Biotechnology (688739.SH) announced that its wholly-owned subsidiary, Liaoning Chengda Biotechnology (Benxi) Co., Ltd. (referred to as "Benxi Subsidiary"), has obtained clinical trial approval from the National Medical Products Administration for its high-dose influenza virus split vaccine and has completed all preparations for Phase I clinical trials, officially entering the Phase I clinical trial stage. The initiation of Phase I clinical trials for the high-dose influenza virus split vaccine indicates a milestone in the product's research and development. Benxi Subsidiary will strictly adhere to clinical trial regulations and protocol requirements, steadily advancing the subsequent clinical research of the product. Differentiated and complementary to the influenza virus split vaccine and quadrivalent influenza virus split vaccine already approved for marketing by the company, this product will further enhance the company's vaccine product lineup in terms of product positioning and target population. If the product successfully completes development and is approved for marketing in the future, it will effectively expand the company's vaccine product pipeline, enrich product structure, and establish a solid foundation for the company's continued and stable development.